LLY
Eli Lilly and Company
LLY has the edge over MXCT overall, supported by stronger fundamentals and lower modeled downside.
MXCT
MaxCyte, Inc.
MXCT trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
MXCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
MXCT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
MXCT PE Valuation
MXCT has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
MXCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect MXCT's revenue to grow, with its earnings and profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over MXCT on earnings quality, reporting a profit while its opponent remains loss making.
MXCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.25 | +$0.19 |
| Q2 2026 | -$0.32 | +$0.11 |
| Q1 2026 | -$0.36 | +$0.04 |
| Q4 2025 | -$0.42 | -$0.03 |
| Q3 2025 | -$0.44 | -$0.10 |
| Q2 2025 | -$0.43 | -$0.09 |
| Q1 2025 | -$0.40 | -$0.05 |
| Q4 2024 | -$0.39 | -$0.02 |
MXCT is still losing money, but less than at its worst: $0.25 per share over the past year, against $0.44 at its worst in late 2025.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over MXCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over MXCT on profitability, with a higher operating margin.
MXCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.2M | +49% |
| Q2 2026 | $7.3M | -15% |
| Q1 2026 | $9.7M | -7.1% |
| Q4 2025 | $7.3M | -16% |
| Q3 2025 | $6.8M | -16% |
| Q2 2025 | $8.5M | -18% |
| Q1 2025 | $10.4M | -8.4% |
| Q4 2024 | $8.7M | -45% |
MXCT's revenue is recovering but still below its 2023 peak: $10M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -60% | +148 points |
| Q2 2026 | -141% | +27 points |
| Q1 2026 | -64% | +54 points |
| Q4 2025 | -154% | -5.4 points |
| Q3 2025 | -207% | -35 points |
| Q2 2025 | -167% | -53 points |
| Q1 2025 | -118% | -10 points |
| Q4 2024 | -148% | -97 points |
MXCT's operating margin was −60% last quarter, up 148 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over MXCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
MXCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.6M | +$2.2M |
| Q2 2026 | -$4.7M | +$5.7M |
| Q1 2026 | -$8.2M | +$6.8M |
| Q4 2025 | -$2.9M | +$5M |
| Q3 2025 | -$7.8M | -$3M |
| Q2 2025 | -$10.4M | -$5.3M |
| Q1 2025 | -$15.1M | -$3.7M |
| Q4 2024 | -$8M | -12010% |
MXCT has burned cash in almost every quarter: −$21M over the past year, against −$41M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
MXCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.1% | -3.3M shares |
| 1 year | -2.9% | -3.1M shares |
| 3 years | +0.1% | +88.2K shares |
| 5 years | +22% | +18.8M shares |
| Available history | +80% | +46.1M shares |
MXCT has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4M |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
MXCT Net Leverage
MXCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
MXCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.2 | Neutral |
| Stochastic | 49.8 | Neutral |
MXCT's weekly RSI is 49 (neutral) and its Stochastic is 50 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
MXCT PE vs Healthcare Sector
MXCT has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over MXCT on trend strength, trading above more of its moving averages.
MXCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.25 | 4.8% below |
| 20 week MA | $1.23 | 3.3% below |
| 50 week MA | $1.12 | 6.2% above |
| 100 week MA | $1.84 | 35% below |
| 200 week MA | $3.06 | 61% below |
MXCT's trend is mixed: it's above one of its five weekly moving averages, and 61% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over MXCT on returns for 2026, with the stronger performance.
MXCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.0 | $10.8 | -36% |
| 2022 | $10.8 | $5.01 | -54% |
| 2023 | $5.01 | $4.70 | -6.2% |
| 2024 | $4.70 | $4.13 | -12% |
| 2025 | $4.13 | $1.61 | -61% |
| 2026 YTD | $1.61 | $1.19 | -26% |
MXCT has finished every year since 2021 lower, and it's down 26% so far in 2026.